Ocuphire Pharma, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 7.11 million compared to USD 5.79 million a year ago. Basic loss per share from continuing operations was USD 0.29 compared to USD 0.28 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.67 USD | -5.11% | -3.47% | -44.52% |
10/05 | Ocuphire Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
11/04 | Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.52% | 45.63M | |
+38.59% | 727B | |
-7.89% | 354B | |
+15.66% | 328B | |
+0.24% | 277B | |
+13.47% | 243B | |
+7.35% | 205B | |
-6.42% | 203B | |
+4.23% | 164B | |
-1.70% | 164B |
- Stock Market
- Equities
- OCUP Stock
- News Ocuphire Pharma, Inc.
- Ocuphire Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024